October 9, 2015 News by Patricia Inacio, PhD Ocrelizumab: Could Genentech/Rocheās Experimental Drug Be the First Effective Progressive MS Therapy? Roche announced positive results for three pivotal Phase III studies of experimental MS therapy ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis (PPMS) patients at this year’s ECTRIMS 2015 conference. The results, particularly for treating PPMS, indicate that the novel therapy may represent…
September 29, 2015 News by Patricia Silva, PhD Could Genentechās Ocrelizumab Become the First Effective Primary Progressive MS Therapy? Genentech, a leading biotechnology company and member of the Roche Group, recently announced promising results on a pivotal Phase III clinical trial (ORATORIO) assessing its investigational therapyĀ ocrelizumab as a treatmentĀ for patients with primary progressive multiple sclerosis (PPMS). Multiple sclerosis (MS) is a chronic, progressive neurodegenerative disorder that results from…
September 17, 2015 News by Malika Ammam, PhD Ocrelizumab: a Promising New Treatment for Multiple Sclerosis with Minimal Side Effects On September 16, 2015, Swiss pharmaceutical company Roche announced that ocrelizumab, a drug originally designed to treat rheumatoid arthritis that saw its development stopped due to an association with infections, could potentially treat relapsing-remitting multiple sclerosis (RRMS) as well as primary progressive MS (PPMS) with minimal sides effects compared…
July 1, 2015 News by Patricia Silva, PhD Rocheās Ocrelizumab Found to be Superior to Standard Interferon Therapy in Relapsing Multiple Sclerosis Patients Roche recently announced encouraging results on its investigational medicine ocrelizumab as a therapy for patients with relapsing multiple sclerosis, which includesĀ either RRMS or SPMS with relapses. Ocrelizumab was evaluated in two pivotal studies (OPERA I and OPERA II), where it was compared to interferon (IFN) beta-1a (RebifĀ®), the standard-of-care…